Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue...

Area of Science:

• Medical Oncology
• Clinical Pharmacology
• Soft Tissue Sarcoma Research

Background:

• Advanced progressive soft tissue sarcomas represent a significant clinical challenge.
• Combination chemotherapy is a standard treatment modality, but optimal scheduling remains under investigation.
• Patient performance status is a known prognostic indicator in various cancers.

Purpose of the Study:

• To compare the efficacy and toxicity of two different combination chemotherapy regimens for advanced soft tissue sarcoma.
• To evaluate the impact of drug administration schedule (simultaneous vs. alternating) on treatment outcomes.
• To determine the prognostic significance of Karnofsky Performance Status (KI) in patients receiving chemotherapy for soft tissue sarcoma.

Main Methods:

• Two hundred forty-six adult patients with advanced progressive soft tissue sarcoma were enrolled.
• Patients were randomly assigned to receive either simultaneous chemotherapy (S1: CYVADIC) or alternating drug pairs (S2: ADIC-CYV) every 4 weeks.
• Response evaluation was based on complete and partial remissions after 8 weeks of treatment; survival and toxicity were also assessed.

Main Results:

• The overall response rate was 26% (18 complete, 25 partial remissions) among 162 evaluable patients.
• The simultaneous regimen (S1: CYVADIC) demonstrated a significantly higher response rate (38%) compared to the alternating regimen (S2: ADIC-CYV) (14%) (P = 0.001).
• Karnofsky Performance Status (KI) was a critical prognostic factor, with patients having KI 90-100 showing a 41% remission rate versus 14% for those with KI 50-80; no patients with KI 50 responded.

Conclusions:

• Simultaneous administration of cyclophosphamide, vincristine, doxorubicin, and dacarbazine (CYVADIC) is more effective in achieving remission for advanced soft tissue sarcoma than alternating drug pairs.
• Karnofsky Performance Status is a highly significant prognostic factor and essential for stratifying patients in clinical trials.
• The observed toxicities were similar between the two regimens, suggesting that scheduling primarily impacts response rates rather than safety profiles.